万年青公告，预计2025年度净利润为2350万元至3500万元，同比增长78.46%至165.79%。2025年预计与 搬迁补偿相关的非经常性损益对归属于上市公司股东的净利润影响约1.6亿元至2.2亿元，最终归属于上 市公司股东的净利润约2350万元至3500万元。 ...

Core Viewpoint - Asia-Pacific Pharmaceutical (002370.SZ) expects a significant increase in net profit for 2025, projecting a range of 100 million to 120 million yuan, representing a growth of 192.06% to 250.47% compared to the previous year [1] Financial Performance - The company anticipates a net profit attributable to shareholders of 100 million to 120 million yuan for 2025, which marks a substantial increase from the previous year [1] - The expected operating revenue for the same period is projected to be between 350 million to 370 million yuan [1] - The company also forecasts a non-recurring loss of 42 million to 60 million yuan [1] Key Drivers - The primary reason for the anticipated profit increase is the sale of the wholly-owned subsidiary, Shaoxing Xingya Pharmaceutical Co., Ltd., with the transaction expected to contribute approximately 149 million yuan to the total profit for 2025 (non-recurring gains) [1]

据中原证券公告，预计2025年度实现归属于母公司所有者的净利润人民币4.00亿元到人民币4.80亿元， 与上年同期相比，将增加人民币1.54亿元到人民币2.34亿元，同比增加62.70%到95.24%。预计2025年度 实现归属于母公司所有者的扣除非经常性损益的净利润人民币4.20亿元到人民币5.00亿元，与上年同期 相比，将增加人民币2.10亿元到人民币2.90亿元，同比增加100.08%到138.19%。 ...

博菲电气公告，预计2025年度净利润为1400万元～1980万元，同比增长5.76%～49.57%。预计扣除非经 常性损益后的净利润为-1500万元～-800万元，上年同期为793.64万元，同比下降289.00%～200.80%。 报告期内，公司净利润变动主要受市场需求回暖、降本增效措施、出售全资子公司产生投资收益及股权 激励计划等因素影响。 ...

公司作为国产血液净化设备的龙头企业，依托技术领先优势和强大的品牌效应，产品市场占有率持续提 升，推动了血液净化设备销售收入的稳步增长。 格隆汇1月30日丨山外山(688410.SH)公布，经财务部门初步测算，预计2025年年度实现归属于母公司所 有者的净利润为14,035.49万元到15,949.42万元，同比增加98%到125%。归属于母公司所有者的扣除非 经常性损益的净利润为13,436.81万元到15,438.03万元，同比增加135%到170%。 ...

格隆汇1月29日丨超捷股份(301005.SZ)公布，预计2025年归属于上市公司股东的净利润1,400万元～ 2,000万元，比上年同期增长31.88%～88.40%，扣除非经常性损益后的净利润1,100万元～1,600万元，比 上年同期增长49.85%～117.96%。 报告期内，公司在市场及客户开发方面取得成效，汽车零部件营收保持稳定增长。公司通过优化生产工 艺、推行精益管理、成本控制等多项措施进行降本增效，着力提升盈利能力。 ...

Group 1 - The core viewpoint of the article is that Chunli Medical has announced an expected significant increase in net profit for the year 2025, projecting a range of 244.988 million to 287.988 million yuan, which represents a year-on-year increase of 120 million to 163 million yuan, equating to a growth of 96.01% to 130.41% [1]

格隆汇1月29日丨普天科技(002544.SZ)公布，预计2025年归属于上市公司股东的净利润1,920万元-2,880 万元，比上年同期增长71.55%-157.33%，扣除非经常性损益后的净利润500万元-750万元。公司预计 2025年度归属于上市公司股东的净利润、扣除非经常性损益后的净利润同比上升，主要原因为：报告期 内专网通信与智慧应用业务，由于推进业务结构优化，强化成本管控，加强回款，实现利润同比上升； 智能制造业务由于特定市场需求回振，实现利润同比上升。 ...

Core Viewpoint - The company, Yatong Co., Ltd., expects to achieve a net profit attributable to shareholders of 14 million to 16.5 million yuan for the year 2025, indicating a significant increase compared to the previous year [1] Financial Performance - The projected net profit represents an increase of 7.6436 million to 10.1436 million yuan compared to the same period last year [1] - This translates to a year-on-year growth of 120.25% to 159.58% [1]

Group 1 - The core viewpoint of the article is that Yiming Pharmaceutical (002826) expects a significant increase in net profit for the fiscal year 2025, projecting a range of 74 million to 102 million yuan, which represents a growth of 61.12% to 122.08% compared to the previous year [1]